GENETIC SIGNATURES LIMITED (GSS)
Share Price Analysis and Chart

11/07/2024

1

Speculative Buy

$1.10

44.74%

Bell Potter raises its target for specialist molecular diagnostics company, Genetic Signatures, to $1.10 from 75c after the transformational milestone of first FDA clearance was achieved last month. Speculative Buy.

First US sales are due in in the 1H of FY25 and Australian sales should revert to growth following the therapeutic Goods Association's (TGA’s) clearance of the revised respiratory test in April.

The broker expects FY25 will be a positive year for the company following the appointment of a globally experienced CEO and an improved balance sheet following the recent capital raise.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -7.90 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.00 cents.

23/05/2024

2

Speculative Outperform

$2.21

190.79%

In a potentially transformational milestone, Taylor Collison points out the final stage is approaching for FDA review of Genetic Signatures' 510(k) application.

The company is seeking clearance to market its EasyScreen gastrointestinal parasite (GIP) test kit in the US. If approved, the analyst is expecting a rapid take-up as the test meets an unmet need, and reimbursement at US$263/test is already in place.

While the broker is expecting a decision before the end of May, there is a moderate risk the FDA review could continue into June.

The Speculative Outperform rating is maintained. Target $2.21.

FORECAST
Taylor Collison forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -13.30 cents.
Taylor Collison forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.40 cents.